Literature DB >> 1628427

T lymphocyte anergy during acute infectious mononucleosis is restricted to the clonotypic receptor activation pathway.

M Pérez-Blas1, J R Regueiro, J R Ruiz-Contreras, A Arnaiz-Villena.   

Abstract

The transient T cell anergy associated with acute infectious mononucleosis (IM) caused by the Epstein-Barr virus has been analysed in a sample of 14 IM children. Peripheral blood mononuclear cells (PBMC) obtained from IM patients showed a significant specific impairment in their proliferative response to both phytohaemagglutinin (PHA; P less than 0.05) and to an anti-CD3 MoAb (P less than 0.001), although both responses reached normal control levels by addition of a submitogenic dose of either phorbol myristate acetate (PMA) or recombinant IL-2 (rIL-2). In contrast, activation signals delivered through other surface molecules (CD2, CD28) or other transmembrane pathways (PMA plus a calcium ionophore) elicited normal or high proliferative responses in most IM PBMC. In a group of five patients tested, the synthesis of IL-2 by IM PBMC in the presence of PMA was impaired when PHA or anti-CD3 was used as stimulus, but it reached normal levels with anti-CD2 or ionophore. Lastly, PHA failed to induce IL-2 alpha receptor (IL-2R alpha) expression in IM PBMC from four tested patients, but the presence of PMA completely corrected this defect. Taken together, these results strongly suggest that the T cell anergy associated with acute IM is due to a T cell receptor (TCR)-specific impairment in the induction of genes involved in T cell proliferation (including those coding for IL-2 and IL-2R alpha) upon membrane signalling to otherwise normal T lymphocytes, since CD2, CD28 and certain transmembrane activation pathways are uncoupled from CD3 in these particular pathological conditions (and perhaps in most in vivo situations). This and other similar experimental approaches to transient secondary immunodeficiencies may help to unravel the physiopathological role of different surface molecules in T cell activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1628427      PMCID: PMC1554405          DOI: 10.1111/j.1365-2249.1992.tb06882.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules.

Authors:  A M Wegener; F Letourneur; A Hoeveler; T Brocker; F Luton; B Malissen
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

2.  Between B cells and T cells.

Authors:  A L DeFranco
Journal:  Nature       Date:  1991-06-20       Impact factor: 49.962

3.  An in vivo functional immune system lacking polyclonal T-cell surface expression of the CD3/Ti(WT31) complex.

Authors:  J R Regueiro; M López-Botet; M O De Landazuri; J Alcami; A Corell; J M Martín-Villa; J L Vicario; A Arnaiz-Villena
Journal:  Scand J Immunol       Date:  1987-12       Impact factor: 3.487

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Activated lymphocytes during acute Epstein-Barr virus infection.

Authors:  B E Tomkinson; D K Wagner; D L Nelson; J L Sullivan
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

6.  Epstein-Barr virus infectious mononucleosis in children. I. Clinical and general laboratory findings.

Authors:  C V Sumaya; Y Ench
Journal:  Pediatrics       Date:  1985-06       Impact factor: 7.124

Review 7.  Epstein-Barr virus and human diseases: recent advances in diagnosis.

Authors:  M Okano; G M Thiele; J R Davis; H L Grierson; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

8.  Mitogenic lectins bind to the antigen receptor on human lymphocytes.

Authors:  O P Chilson; A E Kelly-Chilson
Journal:  Eur J Immunol       Date:  1989-02       Impact factor: 5.532

9.  Comparison of signals delivered through CD3 and CD2 for T-cell activation: the role of calcium influx and interleukin 1.

Authors:  H Wakasugi; Y Mahé; S Huet; L Boumsell; A Bernard; T Tursz
Journal:  Hum Immunol       Date:  1988-11       Impact factor: 2.850

10.  Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies.

Authors:  R A Van Lier; M Brouwer; L A Aarden
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

View more
  6 in total

Review 1.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

2.  Defective functional response to membrane stimuli in lymphocytes from patients with benign prostatic hyperplasia.

Authors:  M Pérez-Blas; B Martínez-Martín; J Carballido; J Hontoria; L I Salazar; C Olivier; M Alvarez-Mon
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

3.  Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection.

Authors:  M Timón; A Arnaiz-Villena; J Ruiz-Contreras; J T Ramos-Amador; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

Review 4.  The lymph node in HIV pathogenesis.

Authors:  Michael M Lederman; Leonid Margolis
Journal:  Semin Immunol       Date:  2008-07-14       Impact factor: 11.130

5.  Limited Utility of Serology and Heterophile Test in the Early Diagnosis of Epstein-Barr Virus Mononucleosis in a Child after Renal Transplantation.

Authors:  Alexandra Byrne; Rachel Bush; Felicia Johns; Kiran Upadhyay
Journal:  Medicines (Basel)       Date:  2020-04-22

6.  T cell receptor signaling pathway is overexpressed in CD4(+) T cells from HAM/TSP individuals.

Authors:  Mariana Tomazini Pinto; Tathiane Maistro Malta; Evandra Strazza Rodrigues; Osvaldo Massaiti Takayanagui; Yuetsu Tanaka; Dimas Tadeu Covas; Simone Kashima
Journal:  Braz J Infect Dis       Date:  2015-09-08       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.